Aviva PLC increased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 16.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 861,017 shares of the company’s stock after acquiring an additional 122,803 shares during the quarter. Johnson & Johnson accounts for 0.8% of Aviva PLC’s portfolio, making the stock its 12th largest position. Aviva PLC’s holdings in Johnson & Johnson were worth $152,839,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. RE Dickinson Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC raised its holdings in Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after acquiring an additional 120 shares during the period. Morton Brown Family Wealth LLC lifted its position in shares of Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares in the last quarter. Professional Financial Advisors LLC boosted its stake in shares of Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after acquiring an additional 68 shares during the period. Finally, Goodman Advisory Group LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $39,000. 68.59% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
JNJ has been the subject of several recent analyst reports. Barclays initiated coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. Atlantic Securities cut their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. UBS Group decreased their target price on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Citigroup reduced their price objective on Johnson & Johnson from $201.00 to $198.00 in a research note on Wednesday, October 5th. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Six investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $184.25.
Johnson & Johnson Price Performance
JNJ stock opened at $171.48 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The stock has a market cap of $448.33 billion, a PE ratio of 23.88, a P/E/G ratio of 3.38 and a beta of 0.57. The company has a 50-day moving average price of $165.92 and a 200 day moving average price of $171.90.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. During the same quarter in the prior year, the firm posted $2.60 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.64%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio is currently 62.95%.
Johnson & Johnson declared that its board has initiated a share buyback plan on Wednesday, September 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 1.2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the business’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.55, for a total value of $2,573,250.00. Following the completion of the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Johnson & Johnson news, insider William Hait sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Peter Fasolo sold 29,275 shares of the stock in a transaction on Monday, October 24th. The stock was sold at an average price of $171.36, for a total value of $5,016,564.00. Following the transaction, the vice president now directly owns 114,676 shares in the company, valued at approximately $19,650,879.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 67,139 shares of company stock worth $11,350,942. Insiders own 0.35% of the company’s stock.
About Johnson & Johnson
(Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Stories
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
